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Abstract
Hepatitis B virus (HBV) is one of the leading health problem with up to 350 million affected people worldwide
including 4.5 million only in Pakistan. It has mortality rate of 0.5 to 1.2 million per year worldwide. Pakistan lies in
the endemic region with 3-5% HBV carrier rate in the country. The present article reviews the literature on the
treatment response of HBV prevalent in Pakistani population. The average treatment response of Lamivudine and
interferon-a is 25.81% and 47.95%, respectively. Peg-Interferon was shown to be not effective against the HBV/HCV
(hepatitis C virus)/HDV (hepatitis Delta virus) co-infection. The present study reveals that interferon-a is the most
effective therapy available for HBV infection prevalent in Pakistani population. Genotype C & D are the most
common HBV genotypes in Pakistan and are associated with increased severity and less response to interferon
therapy. This poses a great challenge for physicians and researchers and further studies are needed to describe the
outcome of the current therapies recommended against HBV infection in Pakistani population.
Introduction
Hepatitis B virus (HBV) is a crucial health problem with
up to 350 million affected people worldwide [1]. HBV is
am e m b e ro ft h eHepadnaviridae family with 3.2 kilo-
base pair DNA genome which is partially double-
stranded [2,3]. Pre-s domain surface protein is mediates
its attachment to the cell membrane [4].
Several previous studies on the association of the HBV
genotypes with disease progression reported that geno-
types B and C are correlated with severity of liver dys-
function while high viral loads were observed in patients
infected with genotype C [5,6], A, and D [7] in some
studies but not in others [8,9]. According to WHO,
Pakistan has low HBV infection rates of 3%, while stu-
dies from Pakistan are more focused towards the HBV
prevalence rate [10,11], epidemiological issues [12], gen-
otyping and its core antigen genetic variability [13].
Approved drugs advised for the treatment of HBV
include interferon-a, PEG-interferon and antiviral drugs
like lamivuaine, adefovir, dipivoxil, entecavir and telbivu-
dine. Hepatitis B antibodies and the HBV vaccine within
12 hours of birth help to prevent the infection [14]. In
Pakistan, there are estimated 4.5 million carriers of HBV
with a carrier rate of 3-5%. However, studies are limited
describing HBV treatment response in Pakistani popula-
tion. The present article reviews all the available litera-
ture on the treatment response to the available therapies
against HBV prevalent in Pakistani population (Table 1).
Anti viral efficacy of lamivudine
A nucleoside analogue called lamivudine, has anti-HBV
and anti-HIV properties, was approved by the US-FDA
in 1998 for the treatment of HBV infections. It is admi-
nistered orally with concentration of 100 mg/day [15].
Use of lamivudine is reported to decrease the circulating
DNA levels of HBV [16,17] while long term decrease
has been achieved after one month’s therapy [18]. In
Pakistani population, the rate of seroconversion against
lamivudine was observed to be 16% in HBV/HDV(Hepa-
titis delta Virus) co-infected patients when administered
for 36 months [19], 23 to 38% in HBV infected patients
when administered for 12 months and 36 months,
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response rate is being observed in Pakistani population
than reported earlier [22]. These studies show that lami-
vudine monotherapy is a better option for treatment of
HBV infection but this therapy require longer durations
(up to 36 months) and develop increased resistance (up
to 20% after one year and 70% after 5 years of therapy)
[23,24], which makes it undesirable for the patients.
Nucleotide and nucleoside analogues are shown to be
associated with minimum side effects as compared to
the standard INF and PEG-INF therapies. These include
short term adversed effects like myopathy, neuropathy
and lactic acidosis [25]. These include side effects like
abdominal pain, headache, cough, nasopharyngitis, pyr-
exia, diarrhea and fatigue [26].
Anti viral efficacy of Peg-Interferon
Interferon is supplemented with polyethylene glycol
(PEG) which prolongs its half-life resulting in sustained
antiviral response rates. Two types of PEG-IFN have
been studied for HBV therapy, PEG-IFN a-2a having
a large 40 kDa PEG branched and PEG-IFN a-2b with
a 12 kDa PEG molecule [27]. Buster and Janssen [22]
reported HBV treatment response of 19-35% by admin-
istration of peg-IFN. However, administration of pegy-
lated interferon-a 2a for 4 months failed to treat the
HBV, HDV and HCV co-infection in Pakistani popula-
tion [20] and is associated with adverse effects like
depression, ﬂu-like symptoms, neuropsychiatric disor-
ders and suppression of bone marrow [28].
This shows that peg-interferon is not effective against
HBV when administered in HBV/HDV/HCV co-infected
patients. However, there is no study describing the use
of peg-interferon against HBV infected Pakistani
population.
Anti viral efficacy of Interferon-a (IFN-a)
IFN-a was approved in 1992 after being extensively stu-
died. It is reported to increase hepatitis B surface anti-
gen (HBsAg) expression by hepatocytes and inhibit
packaging of pre-genomic viral RNA into the core parti-
cles [29]. Currently, many different types of interferon
are available but available data is limited to support
advantage of one therapy to be more effective than the
others. However, the response rate of 30-40% was
reported by the administration of IFN-a for 6-12
months as compared to 10-20% in controls. Patients
with lower ALT and/or higher HBV viral loads and
immunosuppressed patients are the risk factors that
result in decreased response to IFN treatment. Hepatitic
flares are shown to predict sustained virological
response during interferon treatment [30]. Naeem and
coworkers [31] reported that administration of 5MIU of
recombinant IFN-a-2b for four months lead to response
in 44% of Pakistani patients. On the other hand, Zuberi
and colleagues [32] described an increased treatment
response of 51.9% after administration of 10.0 MIU of
IFN-a in HBV infected patients for the same period of
16 weeks. IFN-a is also shown to be associated with the
development of side effects like insomnia, fatigue,
Table 1 An overview of treatment outcome in Pakistani HBV treated patients
Author Region Patients
(n)
Etiology Treatment Duration (weeks) Results
Qureshi
et al: [19]
Karachi 69 HBeAg, HBV DNA
positive patients
100 mg of
Lamivudine orally
before breakfast till
seroconversion
36 months 38% cases were observed to sero-
converted.
Qureshi
et al: [19]
Karachi 55 HBV DNA positive
(wild type) with
delta positive
100 mg of
Lamivudine orally
before breakfast till
seroconversion
36 months 16.4% cases in group 2 sero-converted
(Wild type of HBV/HDV co-infected cases
have a 16% chance of seroconversion)
Naeem
et al: [31]
Rawalpindi 50 Chronic viral
hepatitis B (HBsAg
and HBV DNA
positive)
5 mega units of
recombinant
interferon alfa-2b
subcutaneously once
daily
4-months HBV DNA was found negative in 44.0% (22)
patients while treatment was ceased in
three patients due to severe depression.
Zuberi
et al: [21]
Karachi 246 co/super-infection
of Hepatitis C and
D among patients
of HBV
pegylated interferon-
a 2a 180 mcg sc
weekly
48 weeks HBV was not cleared in any case
Zuberi
et al: [32]
Karachi 52 patients of
hepatitis B with
hepatitis D
Interferon - a 10.0
MIU sc t.i.w.
48 weeks 51.9% patients had suppressed (< 400
copies/ml) HBV DNA levels
Khokhar
et al. [21]
Islamabad 105 positive HBsAg
and elevated ALT
lamivudine 100 mg
once a day for 12
months
12 months and were
followed every 2-3
months with ALT,
HBeAg and HBV DNA
HBeAg positive and HBeAg negative
patients were found with 23.6% and 80.0%
treatment response rate respectively (All
the patients were HBsAg positive)
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on the treatment response and follow up of patients are
needed to understand the effectiveness of INF-a against
HBV infection in Pakistani population.
HBV genetic heterogeneity and Antiviral Therapy
HBV has been classified into 9 genotypes (A-I) based on
8% or more inter-group divergence in full length geno-
mic sequence [35-38] and its antiviral treatment
response rate is highly affected by genetic variability as
well as by various host and viral factors.
The most recent study conducted throughout Pakistan
has reported that HBV genotype C is the most preva-
lent genotype in Pakistan with 26.7% prevalence, fol-
lowed by genotype B (18%), A (14.3%), D (13%), mixed
genotypes (14.6%) and 10.3% were found untypable [38].
While genotypes E (0.6%) and F (1.3%) have been
reported recently in Pakistan. A very high prevalence of
HBV genotype D (60-100%) were also reported from
different regions of Pakistan [39-44,13]. It is well under-
stood that both genotype C & D are less responsive to
interferon therapy and associated with more severe dis-
ease than genotype A and B [45,46]. Moreover, these
genotypes are reported to be less frequently related to
HBeAg clearance rates than genotypes A and B when
treated with pegylated interferon [47]. Another study
revealed that antiviral response rate against IFN-alpha
was higher in genotype F as compared to genotypes E
and G [48].
The high prevalence of HBV genotype D and C in
Pakistani population and its association with increased
s e v e r i t yo ft h ed i s e a s ea n dresistance to the present
therapies demands more consistent preventive measures
like mass vaccination and awareness programs at
national level.
Conclusion
This review explains that interferon-a is the most effec-
tive available drug against the HBV prevalent in Pakistan
with up to 47.95% treatment response rate. Moreover,
treatment of the resistant but most prevalent HBV gen-
otypes C and D is a challenge for clinicians and scien-
tists in our region. However, further studies are needed
to fully describe the treatment response and the risk fac-
tors of the currently recommended therapies against
HBV infection especially combination therapy of inter-
feron and lamivudine in Pakistani isolates. These future
prospects will enable the virologists to focus drug
designing in this part of the world.
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